Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Byrd

Showing results (221-230 of 1,058) with videos related to

Pageof 106
Sort By:
JAMA Dermatology|November 29, 2016
Sweet-Like Eruption Associated With Obinutuzumab Therapy for Chronic Lymphocytic LeukemiaAbraham M Korman, Justin G Hastings, John C Byrd, et al.
Seminars in Oncology|March 3, 1998
Old and new therapies in chronic lymphocytic leukemia: now is the time for a reassessment of therapeutic goalsJ C Byrd, K R Rai, E A Sausville, et al.
The Journal of Chemical Physics|December 9, 2024
A nonequilibrium kinetic model of high-resolution vibrational energy transfer in RDX from selective IR excitationZhiyu Liu, Iskander G Batyrev, Edward F C Byrd, et al.
Archives of Dermatological Research|December 19, 2023
Dermatologic conditions in dancers: a statewide surveyRyan C Saal, Joshua F Edwards, Scott M Whitlock, et al.
The Journal of Biological Chemistry|August 30, 2000
Phosphorylation of the beta-galactoside-binding protein galectin-3 modulates binding to its ligandsN Mazurek, J Conklin, J C Byrd, et al.
Cancer|March 30, 2011
A galectin-3 sequence polymorphism confers TRAIL sensitivity to human breast cancer cellsNachman Mazurek, James C Byrd, Yunjie Sun, et al.
The FEBS Journal|February 25, 2009
High-affinity ligand binding by wild-type/mutant heteromeric complexes of the mannose 6-phosphate/insulin-like growth factor II receptorMichelle A Hartman, Jodi L Kreiling, James C Byrd, et al.
Neurobehavioral Toxicology|January 1, 1979
A method for the routine assessment of fore- and hindlimb grip strength of rats and miceO A Meyer, H A Tilson, W C Byrd, et al.
British Journal of Haematology|December 3, 1999
Clonal selection of CD56+ t(8;21) AML blasts: further suggestion of the adverse clinical significance of this biological marker?J T Daniels, B J Davis, L Houde-McGrail, et al.
Journal of General Internal Medicine|May 1, 1996
Physician extenders for cost-effective management of hypercholesterolemiaG Schectman, N Wolff, J C Byrd, et al.
Pageof 106

Showing results (221-230 of 1,058) with videos related to

Sort By:
Pageof 106
JAMA Dermatology|November 29, 2016
Sweet-Like Eruption Associated With Obinutuzumab Therapy for Chronic Lymphocytic LeukemiaAbraham M Korman, Justin G Hastings, John C Byrd, et al.
Seminars in Oncology|March 3, 1998
Old and new therapies in chronic lymphocytic leukemia: now is the time for a reassessment of therapeutic goalsJ C Byrd, K R Rai, E A Sausville, et al.
The Journal of Chemical Physics|December 9, 2024
A nonequilibrium kinetic model of high-resolution vibrational energy transfer in RDX from selective IR excitationZhiyu Liu, Iskander G Batyrev, Edward F C Byrd, et al.
Archives of Dermatological Research|December 19, 2023
Dermatologic conditions in dancers: a statewide surveyRyan C Saal, Joshua F Edwards, Scott M Whitlock, et al.
The Journal of Biological Chemistry|August 30, 2000
Phosphorylation of the beta-galactoside-binding protein galectin-3 modulates binding to its ligandsN Mazurek, J Conklin, J C Byrd, et al.
Cancer|March 30, 2011
A galectin-3 sequence polymorphism confers TRAIL sensitivity to human breast cancer cellsNachman Mazurek, James C Byrd, Yunjie Sun, et al.
The FEBS Journal|February 25, 2009
High-affinity ligand binding by wild-type/mutant heteromeric complexes of the mannose 6-phosphate/insulin-like growth factor II receptorMichelle A Hartman, Jodi L Kreiling, James C Byrd, et al.
Neurobehavioral Toxicology|January 1, 1979
A method for the routine assessment of fore- and hindlimb grip strength of rats and miceO A Meyer, H A Tilson, W C Byrd, et al.
British Journal of Haematology|December 3, 1999
Clonal selection of CD56+ t(8;21) AML blasts: further suggestion of the adverse clinical significance of this biological marker?J T Daniels, B J Davis, L Houde-McGrail, et al.
Journal of General Internal Medicine|May 1, 1996
Physician extenders for cost-effective management of hypercholesterolemiaG Schectman, N Wolff, J C Byrd, et al.
Pageof 106